IL36G: A Potential Drug Target and Biomarker (G56300)

Target Name: IL36G

NCBI ID: G56300

IL36G

IL36G: A Potential Drug Target and Biomarker

Interleukin 36 gamma (IL36G), a protein that belongs to the interleukin 36 family, has been identified as a potential drug target and biomarker for various diseases, including cancer, cardiovascular diseases, and autoimmune disorders. Its functions and interactions with other molecules have led to a growing interest in it as a potential therapeutic agent.

IL36G is a cytokine that is expressed in various tissues and cells, including immune cells, epithelial cells, and nervous cells. It plays a crucial role in the regulation of immune responses, inflammation, and tissue repair. One of its well-known functions is its role in cancer progression. IL36G has been shown to promote the growth and survival of various cancer cell types, including breast, ovarian, and colorectal cancer.

In addition to its role in cancer, IL36G has also been linked to a number of other diseases and conditions. For example, it has been found to be elevated in individuals with autoimmune disorders, such as rheumatoid arthritis and lupus. It has also been shown to be involved in the development and progression of cardiovascular diseases, including heart failure, coronary artery spasms, and stroke.

The potential drug targets for IL36G are vast, and include modulating its activity in various ways, such as inhibiting its signaling pathways, reducing its levels, or blocking its interactions with other molecules. One of the most promising approaches to targeting IL36G is the use of small molecules, such as those derived from natural products or synthesis. These molecules can be designed to specifically interact with IL36G and modulate its activity, providing a potential source of therapeutic agents.

Another approach to targeting IL36G is the use of monoclonal antibodies (MCAs), which are laboratory-produced molecules that can bind to a specific target molecule with high affinity. MCAs have been shown to be effective in targeting a wide range of molecules, including IL36G, and can be used to inhibit its signaling pathways or enhance its downregulation. The use of MCAs provides a potential mechanism for targeting IL36G and may be a promising approach for the development of new therapeutic agents.

In addition to its potential as a drug target and biomarker, IL36G has also been shown to be a potential biomarker for various diseases. For example, its levels have been shown to be elevated in individuals with certain cancers, and it has been used as a marker for disease progression in individuals with autoimmune disorders. The use of IL36G as a biomarker may have implications for the early detection and diagnosis of these diseases, as well as for the development of new diagnostic tests.

Overall, the potential of IL36G as a drug target and biomarker has led to a growing interest in its study and potential therapeutic applications. Further research is needed to fully understand its functions and interactions, as well as to develop new approaches for its targeting and use as a therapeutic agent. With continued research and development, IL36G has the potential to become a valuable tool for the treatment of a wide range of diseases.

Protein Name: Interleukin 36 Gamma

Functions: Cytokine that binds to and signals through the IL1RL2/IL-36R receptor which in turn activates NF-kappa-B and MAPK signaling pathways in target cells. Part of the IL-36 signaling system that is thought to be present in epithelial barriers and to take part in local inflammatory response; similar to the IL-1 system with which it shares the coreceptor IL1RAP. Seems to be involved in skin inflammatory response by acting on keratinocytes, dendritic cells and indirectly on T-cells to drive tissue infiltration, cell maturation and cell proliferation. In cultured keratinocytes induces the expression of macrophage, T-cell, and neutrophil chemokines, such as CCL3, CCL4, CCL5, CCL2, CCL17, CCL22, CL20, CCL5, CCL2, CCL17, CCL22, CXCL8, CCL20 and CXCL1; also stimulates its own expression and that of the prototypic cutaneous pro-inflammatory parameters TNF-alpha, S100A7/psoriasin and inducible NOS. May play a role in pro-inflammatory responses during particular neutrophilic airway inflammation: activates mitogen-activated protein kinases and NF-kappa B in primary lung fibroblasts, and stimulates the expression of IL-8 and CXCL3 and Th17 chemokine CCL20 in lung fibroblasts. May be involved in the innate immune response to fungal pathogens, such as Aspergillus fumigatus

The "IL36G Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IL36G comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets